Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies
- 1 May 1995
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 6 (5) , 467-476
- https://doi.org/10.1093/oxfordjournals.annonc.a059217
Abstract
Background: Interferon (IFN) treatment trials in multiple myeloma have yielded discordant results regarding response rates, maintenance duration, and survival times. Further randomized trials and global evaluations of available data are urgently needed for clarification. Patients and methods: 256 patients participated in a randomized trial, 125 on IFN + VMCP, and 131 on VMCP alone. 100 patients were randomized to IFN maintenance (n – 46) or were untreated controls (n – 54). Global evaluations are based on 1,518 patients in induction and 924 in maintenance trials. Results: The induction trial demonstrated a significantly (pConclusions: Presently available data support the use of IFN maintenance treatment because it significantly prolongs maintenance duration and survival. IFN added to induction chemotherapy resulted in minor improvements at the expense of increased toxicity, highlighting the need for better induction regimens.Keywords
This publication has 23 references indexed in Scilit:
- Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central SwedenBlood, 1993
- A Randomised Trial of Cyclophosphamide With and Without Low Dose Alpha-Interferon in the Treatment of Newly Diagnosed MyelomaLeukemia & Lymphoma, 1993
- α-Interferon Combination Therapy of Resistant MyelomaAmerican Journal of Clinical Oncology, 1991
- Alpha‐2a‐interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myelomaBritish Journal of Haematology, 1990
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group StudyLeukemia & Lymphoma, 1990
- High doses of natural α‐interferon (α‐IFN) in the treatment of multiple myeloma — A pilot study from the Myeloma Group of Central Sweden (MGCS)European Journal of Haematology, 1988
- Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trialEuropean Journal of Cancer and Clinical Oncology, 1986
- Biochemical pathways in interferon-actionPharmacology & Therapeutics, 1984
- Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assayCancer Chemotherapy and Pharmacology, 1983